In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Allogene Therapeutics Inc (NASDAQ: ALLO) was $1.62 for the day, down -4.71% from the previous closing price of $1.70. In other words, the price has decreased by -$4.71 from its previous closing price. On the day, 3.08 million shares were traded.
Ratios:
Our analysis of ALLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.54 and its Current Ratio is at 8.54. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.Piper Sandler initiated its Overweight rating on May 31, 2024, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 21 ’25 when Yoshiyama Annie sold 9,601 shares for $1.41 per share. The transaction valued at 13,537 led to the insider holds 130,663 shares of the business.
Yoshiyama Annie bought 9,601 shares of ALLO for $13,537 on Apr 21 ’25. On Mar 14 ’25, another insider, Chang David D, who serves as the President and CEO of the company, sold 46,668 shares for $1.96 each. As a result, the insider received 91,469 and left with 5,276,569 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 17715.00 while its Price-to-Book (P/B) ratio in mrq is 0.81.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $1.23. The 50-Day Moving Average of the stock is -3.23%, while the 200-Day Moving Average is calculated to be -27.44%.
Shares Statistics:
A total of 212.21M shares are outstanding, with a floating share count of 142.26M. Insiders hold about 34.52% of the company’s shares, while institutions hold 63.38% stake in the company.
